Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Gestin de Proyectos CTeI en Ciencia Abierta, MGA, Cooperacin Internacional, entre otros
These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the risks that are discussed more fully in our filings with the Securities and Exchange Commission (the SEC) including the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 24, 2026, and other documents we subsequently file with or furnish to the SEC, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 12, 2026
A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes
The condition encompasses a spectrum of pathophysiologic processes ranging from absolute insulin deficiency (Type 1) to progressive insulin secretory failure superimposed on insulin resistance (Type 2)
US$ 27.17
US$ 26.00
US$ 29.50
US$ 26.74
US$ 23.39
US$ 24.24
US$ 28.45
